MedTecpinion’s approach to reducing the total cost of oncology care

A cancer diagnosis rarely follows a simple path.

There may be an initial consultation, imaging, surgery or chemotherapy, follow-up visits, medicines, complications, emergency care and sometimes an unexpected hospital stay. For the patient, it is one continuous journey. For the healthcare system, however, these events are often recorded, managed and paid for separately.

That gap is becoming harder to ignore.

The latest WHO Global Status Report on Cancer, released in 2026, estimates 20.6 million new cancer cases and nearly 10 million cancer deaths globally each year. Without stronger action, annual cancer cases are projected to reach nearly 35 million by 2050.

The question is no longer only how to treat cancer better. It is also how to understand the full cost of treating it.

This is where MedTecpinion sees an opportunity.

The company is developing an Episode-Based Oncology Intelligence Management Platform that brings clinical and financial information into one view. Instead of looking at each visit or bill in isolation, the platform is designed to follow an oncology episode from the moment a treatment pathway begins through monitoring, episode closure and financial reconciliation.

The idea is simple: understand the expected cost early, track what happens as treatment progresses, and identify problems before they become expensive surprises.

This approach also reflects a broader shift in healthcare toward models that look beyond individual treatments and focus on the entire episode of care. Across different healthcare systems, providers and payers are increasingly looking for ways to connect treatment decisions with quality, outcomes and the total cost of a patient’s journey.

For MedTecpinion, technology can help make that accountability more practical.

Its platform is designed to give oncologists and care teams real-time visibility into episode costs, while helping hospitals identify avoidable acute-care use and optimise treatment pathways. Its model targets a 10–25% reduction in total cost of care and highlights potential reductions in avoidable hospitalisations and better pathway adherence.

The bigger idea is not simply about reducing spending.

It is about connecting two conversations that have traditionally happened in different rooms: What is clinically right for the patient? And what does the entire episode of care actually cost?

That conversation comes at an important time for Asia’s healthcare sector, where a growing cancer burden is meeting rapidly evolving healthcare technology and increasing pressure to deliver better outcomes with sustainable costs. The Asia-Pacific MedTech market is already worth more than US$140 billion and is projected to grow at a CAGR of 8.4% between 2024 and 2029, according to figures highlighted by MedTech World.

MedTecpinion will bring this perspective to MedTech World Asia 2026, taking place at the Hong Kong Convention and Exhibition Centre from 26–28 August. The three-day event will bring together healthcare innovators, investors, clinicians, hospital leaders and policymakers to discuss how technology can move from promising ideas to real-world healthcare impact.

Because the future of oncology will not only depend on discovering better treatments. It will also depend on building smarter systems around the patient journey.

Better care needs better visibility. And sometimes, seeing the whole picture is where change begins.